Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer
Defining high risk, considering role of Ki-67, BRCA mutations
Source: medpagetoday.com
📰 Virtual Plenary News
Page 3 - Virtual Plenary News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Virtual Plenary. Real-time updates on events, politics, business and more.
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today provided an...
Source: prnewswire.com
An 'Intriguing Failure' in Advanced, Pre-Treated GIST
Second-line ripretinib unable to best sunitinib, but still had meaningful clinical activity
United States Dana Farber Cancer Institute Vicki Keedy Michael Heinrich Mike Bassett Ripretinib Qinlock
Source: medpagetoday.com
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung…
SAN FRANCISCO and SUZHOU, China, Dec. 24, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for...
Source: asiaone.com
Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed…
SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced first interim analysis results of the randomized, double-blinded, multi-center Phase 3 ORIENT-31 study conducted in China evaluating sintilimab...
United States Hong Kong Adimab Incyte Eli Lilly European Society For Medical Oncology Virtual Plenary Md Anderson Cancer Center
Source: asiaone.com
Positive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary
/PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free...
Source: prnewswire.com